Immuneering Corporation remote jobs and company guide

Immuneering is a clinical-stage oncology company dedicated to developing a new class of cancer therapies called Deep Cyclic Inhibitors, designed to outpace cancer adaptation and improve durability of treatment while preserving patient quality of life. Founded with a singular vision to help people with cancer live longer without compromising their quality of life during treatment, the company has established itself as a leader in targeting MAPK-driven cancers.

The company is developing its lead Deep Cyclic Inhibitor, atebimetinib, currently being advanced in pancreatic cancer and lung cancer, with plans to evaluate its potential in other MAPK-pathway cancers. Since the MAPK pathway is activated in roughly half of all cancers, Deep Cyclic Inhibitors have relevance across a broad spectrum of tumor types. Immuneering operates from headquarters in Cambridge, MA, with additional offices in New York and San Diego. The company is publicly traded on Nasdaq under the ticker symbol IMRX and has presented compelling clinical data, including 17.3-month median overall survival in first-line pancreatic cancer patients.